Project Details
Description
Public Health Relevance Statement/Narrative
Persistent reservoirs of cells latently infected by human immunodeficiency virus (HIV-1) can potentially be
reactivated to produce virus, creating impediments to HIV-1 eradication or cure. CD4-mimetic compounds
sensitize virus-expressing cells to antibody-dependent cellular cytotoxicity (ADCC). The objective of this
proposal is to provide a proof of concept for the value of conjugates of a CD4-mimetic compound, M48U1, with
potent ADCC-mediating antibodies recognizing highly-conserved epitopes on HIV-1 envelope glycoproteins for
their ability in reducing the size of the viral reservoir which could expedite application to HIV-1-infected
humans.
Status | Finished |
---|---|
Effective start/end date | 1/07/17 → 30/06/22 |
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: $498,498.00
- National Institute of Allergy and Infectious Diseases: $448,961.00
- National Institute of Allergy and Infectious Diseases: $456,569.00
- National Institute of Allergy and Infectious Diseases: $2,333,272.00
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: $484,873.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.